Nebraska Cancer Specialists Advances Cancer Care with Outpatient CAR T-Cell Therapy
Nebraska Cancer Specialists Advances Cancer Care with Outpatient CAR T-Cell Therapy
Innovative treatment expands access to advanced cellular therapy in a community oncology setting.
Nebraska Cancer Specialists (NCS) continues to advance the future of cancer care by offering chimeric antigen receptor (CAR) T-cell therapy in an outpatient setting, marking a significant milestone for community oncology in Nebraska.
CAR T-cell therapy is a groundbreaking form of immunotherapy that harnesses the power of a patient’s own immune system to identify and fight cancer cells. This highly specialized treatment offers new hope for patients with certain blood cancers, including lymphoma, leukemia and multiple myeloma.
Traditionally administered with an extended hospital stay, CAR T-cell therapy in an outpatient setting allows eligible patients to spend more time in the comfort of their own homes, surrounded by loved ones, while receiving close monitoring and specialized care from their oncology team.
“Bringing CAR T-cell therapy into the outpatient setting represents an extraordinary advancement in how we deliver cancer care,” said Joel Michalski, MD, PhD, hematologist and oncologist at Nebraska Cancer Specialists. “We are not only expanding access to some of the most innovative treatments available today, but also transforming the patient experience.”
This reflects Nebraska Cancer Specialists’ ongoing commitment to bringing the latest advancements in personalized cancer care to patients in Nebraska. By expanding access to advanced cellular therapies within community oncology, NCS continues to bring the future of cancer treatment closer to home.
